Related Experiment Video
Updated: Aug 16, 2026
A Human Glioblastoma Organotypic Slice Culture Model for Study of Tumor Cell Migration and Patient-specific Effects of Anti-Invasive Drugs
Published on: July 20, 2017
Molecular biology of gliomas
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Lassmana@mskcc.org
Abstract:
Gliomas are the most common primary neoplasm of the brain. Unfortunately, they are often refractory to treatment and portend a poor prognosis. However, recent discoveries have shed light on the molecular events driving glioma growth, including abnormalities of three major molecular pathways: extracellular growth factors and their receptors (eg, EGF/EGFR and PDGF/PDGFR), signal transduction cascades (eg, RAS and AKT), and cell proliferation controls (eg, INK4A-ARF). Each of these abnormalities is described in detail. Efforts to inhibit abnormally activated pathways are underway through multi-institutional clinical trials.
Insights
Gliomas, common brain tumors, resist treatment due to molecular pathway abnormalities. Targeting these pathways, including growth factors, signal transduction, and cell proliferation, offers new therapeutic strategies.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Gliomas represent the most frequent primary brain tumors.
- These tumors are often resistant to current therapeutic interventions, leading to poor patient prognoses.
Purpose of the Study:
- To elucidate the key molecular abnormalities driving glioma pathogenesis.
- To highlight potential therapeutic targets within identified molecular pathways.
Main Methods:
- Review and synthesis of recent discoveries in glioma molecular biology.
- Detailed description of abnormalities in growth factor signaling, signal transduction cascades, and cell cycle control pathways.
Main Results:
- Identified critical molecular aberrations in three major pathways: extracellular growth factors/receptors (EGF/EGFR, PDGF/PDGFR), signal transduction (RAS, AKT), and cell proliferation (INK4A-ARF).
- Detailed characterization of each pathway's aberrant molecular events in glioma.
Conclusions:
- Understanding these molecular drivers is crucial for developing effective glioma treatments.
- Ongoing multi-institutional clinical trials are investigating inhibitors of these abnormally activated pathways.
